GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (FRA:2Q5) » Definitions » Research & Development

Renovaro (FRA:2Q5) Research & Development : €3.02 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Renovaro Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Renovaro's Research & Development for the three months ended in Mar. 2024 was €1.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €3.02 Mil.

Renovaro Research & Development Historical Data

The historical data trend for Renovaro's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Research & Development Chart

Renovaro Annual Data
Trend Mar13 Dec14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.21 4.17 13.05 7.92 3.84

Renovaro Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.92 0.53 0.57 1.00

Renovaro Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renovaro  (FRA:2Q5) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Renovaro Research & Development Related Terms

Thank you for viewing the detailed overview of Renovaro's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovaro (FRA:2Q5) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (FRA:2Q5) » Definitions » Research & Development
Comparable Companies
AEON SCPH INZY ENTA MCRB IVVD GRTS DNTH CBUS PSTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RENB:USA 2Q5:Germany
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Website
https://www.enochianbio.com
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.

Renovaro (FRA:2Q5) Headlines

No Headlines